BusinessJun 22, 2026
Wall Street Is Chasing a Peptide Market Finally Ready to Go Legal
Rhea Lobo
Call it the shot heard around the wellness world. A black-market peptide economy worth up to $3B is on the cusp of going legal, thanks to a peptide-friendly White House and an upcoming FDA advisory panel meeting in late July. The industry is now nearing its largest inflection point yet.
Riding the wave: The peptide black market exploded as consumers who discovered GLP-1 weight-loss drugs went looking for more. The FDA’s Pharmacy Compounding Advisory Committee will soon decide whether seven peptides can be legally compounded. Health Secretary Robert F. Kennedy Jr. says the move would help replace an underground market with regulated access. Telehealth companies, compounding pharmacies, and investors are hoping to capture the boom.
The opportunity looks sizable, but it’s highly sensitive to regulation. Leerink Partners projects the telehealth peptide market could reach $2.2B by 2027, with Hims & Hers Health potentially capturing ~$440M. In a more conservative scenario where providers prescribe fewer peptides, the firm cuts its market estimate to $1.1B and Hims’ revenue opportunity to ~$220M, underscoring how wide the range of outcomes remains. The field is quickly filling up.
The regulatory tightrope: The FDA recently issued 25 warning letters to telehealth companies over misleading claims about compounded GLP-1 drugs, showing that legalization won't mean a free-for-all. Supply chains still rely heavily on Chinese manufacturers, and scaling production will take time to establish regulatory-compliant sourcing. The peptide race has begun, but compliance may prove to be the ultimate performance enhancer.
